The ISAPP consensus definition (Hill et al., Nature Reviews Gastroenterology & Hepatology, 2014, PMID 24912386) emphasises that probiotic benefits should be read in relation to the specific strains and the studied dose, so a headline CFU number alone does not define a probiotic's strength. This UK evidence guide covers what CFU means, CFU at manufacture versus expiry, strain identity versus strain count, refrigerated versus shelf-stable storage, higher-dose safety, and how 50, 100 and 450 billion products compare, including CDS22-formula, the original 8-strain De Simone Formulation (450 billion CFU per sachet, £19.95) with UK cold-chain delivery.

Barnes et al. (American Gastroenterological Association, Gastroenterology 2024;166(1):59-85, PMID 38128971) state that the evidence favouring probiotics for preventing recurrent pouchitis is limited to the De Simone Formulation, based on three randomised trials showing an 87% lower relapse risk over 12 months (RR 0.17; 95% CI 0.09-0.34; low certainty of evidence). This UK reference guide explains exactly what the AGA guideline says and does not say, the verified PMIDs, why product names in older papers are unreliable, and how the formulation is supplied today as CDS22-formula (8 NCIMB strains, 450 billion CFU), a food supplement under FSA rules, not a medicine..

CDS22-formula, an 8-strain live bacteria food supplement providing 450 billion CFU per sachet, was exhibited at BSG LIVE'26, the British Society of Gastroenterology's annual congress, held at ACC Liverpool from 22 to 25 June 2026. This update covers the event, what was shared at the stand with gastroenterology professionals, and how CDS22-formula is supplied across the UK and Ireland through Probiotic.co.uk and Probiotic.ie under FSA and FSAI food supplement rules. Exhibiting at a congress is not an endorsement by the British Society of Gastroenterology.

Whorwell et al. (University of Manchester, Am J Gastroenterol, 2006, PMID 16863564) demonstrated significant improvement in IBS composite symptom scores within 4 weeks using Bifidobacterium infantis 35624 at 1×10⁸ CFU/day, while Gionchetti et al. (Gastroenterology, 2000, PMID 10930365) measured 85% pouchitis remission maintenance at 9 months with the De Simone Formulation versus 6% in placebo, establishing published timing benchmarks for probiotic response in UK-relevant clinical populations. This UK evidence guide covers the signs probiotics are working by body system, how long probiotics take to work by use case (IBS, bloating, after antibiotics, women's health), signs they are not working, and CDS22-formula (8 NCIMB strains, 450 billion CFU, £19.50 per 12-sachet pack, cold-chain delivered by Probiotic.co.uk).

Barnes et al. (American Gastroenterological Association, Gastroenterology 2024;166(1):59-85, PMID 38128971) stated that evidence favouring probiotics for preventing pouchitis recurrence is "limited to the De Simone Formulation" — the 8-strain, 450 billion CFU formulation sold in the UK as CDS22-formula (NCIMB-coded strains, cold-chain delivered, £19.50 per 12-sachet pack). This UK evidence guide covers what makes a probiotic "clinical grade", compares Symprove, Alflorex (B. infantis 35624), Optibac, Bio-Kult and CDS22-formula by published RCT data, covers FSA regulatory status, and includes a "signs probiotics are working" timeline from Probiotic.co.uk, regulated under UK food supplement legislation.

Clinical trials on the De Simone Formulation — an 8-strain, 450 billion CFU probiotic blend — demonstrate statistically significant reductions in abdominal bloating and flatulence in IBS patients (Kim et al., Mayo Clinic, 2003 and 2005). This evidence-based guide covers the gut microbiome science behind bloating, strain-specific RCT data, and how UK consumers can identify a clinically researched probiotic for bloating and gas.

ECCO stated in October 2023 that the De Simone Formulation was sold under the VSL#3 brand until 2016, and that the product sold as VSL#3 after 2016 no longer contains it. The AGA 2024 pouchitis guideline (Barnes et al., Gastroenterology 2024;166(1):59-85, PMID 38128971) names the De Simone Formulation as the probiotic used in the trials it reviewed; that recommendation is conditional, based on low-certainty evidence, and applies to secondary prevention of recurrent pouchitis only. This UK guide sets out the brand history, the current CDS22-formula NCIMB strain list and the US false-advertising findings, with every statement attributed to the source that published it. No clinical trial has been conducted on CDS22-formula under that product name. CDS22-formula is a food supplement, not a medicine, available from Probiotic.co.uk, the sole exclusive distributor for the UK and Ireland (from £19.95, free cold-chain UK delivery over £65). Probiotic.co.uk sells CDS22-formula and is not affiliated with the VSL#3, Vivomixx or Visbiome trademark holders.

"Intensive bowel support" is UK consumer shorthand, not a medical term. This guide sets out what it usually means, what counts as high-strength in CFU terms, what published research has examined and in which populations, the UK rules on nutrition and health claims, and a checklist for assessing a product by strain list and deposit code rather than marketing language.

CDS22 sachets deliver 450 billion CFU across 8 clinically studied De Simone strains versus Optibac Every Day's 5 billion CFU single-strain formula. This comparison covers strain diversity, clinical trial evidence, and cost-per-dose for UK buyers choosing between everyday maintenance and specialist gut support.

This UK guide reviews the clinical evidence for probiotics in ulcerative colitis, IBS and pouchitis, drawing on the primary randomised trials, including Gionchetti et al. (Gastroenterology, 2000 and 2003) in pouchitis, Sood et al. (2009) and Tursi et al. (2010) in ulcerative colitis, and Kim et al. (2003) in IBS. It explains where the De Simone Formulation has the strongest data, where the evidence is mixed, and why any probiotic should be used alongside standard care and discussed with your IBD team.

CDS22 delivers 450 billion CFU across 8 De Simone strains with clinical trial evidence for IBS, ulcerative colitis, and pouchitis; Symprove is a liquid single-strain formula studied primarily in IBS-D. This comparison covers delivery mechanism, strain specificity, CFU potency, and clinical evidence for UK buyers.

Vivomixx 450 was discontinued by Mendes SA in 2025 and Vivomixx Neo is marketed as a separate product with a different strain list. This UK guide compares CDS22-formula, an 8-strain 450 billion CFU supplement manufactured by EOS2021 S.r.l. with strains identified by NCIMB deposit codes 30435 to 30442, against Vivomixx Neo using each manufacturer's own published information.